person · Reporting owner

GUSTAFSON KURT A

Disclosed activity across 5 companies

Tapewire entity: 31436
SEC CIK: 0001462354

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Niagen Bioscience, Inc.CDXC · Entity 6146	Director	June 17, 2021	June 22, 2021
OmniAb, Inc.OABI · Entity 5294	Executive VP, Finance and CFO	April 07, 2026	April 08, 2026
SPECTRUM PHARMACEUTICALS INCSPPI · Entity 111009	EVP & Chief Financial Officer	March 15, 2022	March 16, 2022
Xencor IncXNCR · Entity 4487	Director	June 16, 2026	July 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Niagen Bioscience, Inc.

Report date June 17, 2021 · Filed June 22, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.99 · Expires 2031-06-16	Direct	20,000	Reported balance After 2021-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-17 · Grant · Acquired 20,000 · Balance 20,000 F1: Options vest 100% on June 17, 2022

Filing footnotes · ownership attribution and instrument terms

F1: Options vest 100% on June 17, 2022

OmniAb, Inc.

Report date April 07, 2026 · Filed April 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	268,396	Reported balance After 2026-04-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-04-07 · Exercise / conversion · Acquired 13,542 · Balance 268,396 F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The total includes the transfer of 13,997 OABI common stock shares on March 11, 2026 to the reporting person's ex-spouse per a domestic relations order.
Common StockSEC Table I · non-derivative	Direct	261,483	Reported balance After 2026-04-07 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-04-07 · Sale · Disposed 6,913 · Balance 261,483 F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	111,042	Reported balance After 2026-04-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-07 · Exercise / conversion · Disposed 13,542 · Balance 111,042 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F3: The total includes the transfer of 13,997 OABI common stock shares on March 11, 2026 to the reporting person's ex-spouse per a domestic relations order.

F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SPECTRUM PHARMACEUTICALS INC

Report date March 15, 2022 · Filed March 16, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par valueSEC Table I · non-derivative	Direct	317,259	Ending reported balance After 2022-03-16 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-03-15 · Sale · Disposed 20,653 · Balance 333,577 F1: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Row 2 · 2022-03-16 · Sale · Disposed 16,318 · Balance 317,259 F1: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer.
Common Stock, $0.001 par valueSEC Table I · non-derivative	IndirectBy 401(k) Plan	11,840	Reported balance Holding disclosure · report date 2022-03-15 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 11,840

Filing footnotes · ownership attribution and instrument terms

F1: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer.

Xencor Inc

Report date June 16, 2026 · Filed July 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	25,011	Reported balance After 2026-06-16 transaction · row 1 1 source row Row 1 · 2026-06-16 · Grant · Acquired 10,302 · Balance 25,011 F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.20 · Expires 2036-06-15	Direct	20,604	Reported balance After 2026-06-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-16 · Grant · Acquired 20,604 · Balance 20,604 F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant.

F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

OmniAb Operations, Inc.

Report date November 01, 2022 · Filed November 04, 2022

Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2022-11-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-11-01 · Grant · Acquired 17,792 · Balance 17,792 F1: Includes 14,234 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. Row 2 · 2022-11-01 · Disposition to issuer · Disposed 17,792 · Balance 0 F2: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $60.68 · Expires 2032-04-08	Direct	71,174	Reported balance After 2022-11-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-11-01 · Grant · Acquired 71,174 · Balance 71,174 F3: The stock option vests and is exercisable as to 12.5% of the underlying shares on October 8, 2022, and in 42 substantially equal monthly installments thereafter.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $60.68 · Expires 2032-04-08	Direct	0	Reported balance After 2022-11-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-11-01 · Disposition to issuer · Disposed 71,174 · Balance 0 F2: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: The stock option vests and is exercisable as to 12.5% of the underlying shares on October 8, 2022, and in 42 substantially equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 14,234 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.

F2: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.

F3: The stock option vests and is exercisable as to 12.5% of the underlying shares on October 8, 2022, and in 42 substantially equal monthly installments thereafter.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 07, 2023 Filed Dec 12, 2023 00:51 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionRestricted Stock Units · Derivative	46,503	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0002001011-23-000010 · primary_doc.xml · derivative · entry 6 GUSTAFSON KURT A · CIK 0001462354 · Executive VP, Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,124 Underlying: Common Stock · 46,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three substantially equal annual installments beginning on December 07, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. F1 · derivative.exercise_date: Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three substantially equal annual installments beginning on December 07, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. F1 · derivative.expiration_date: Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three substantially equal annual installments beginning on December 07, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document
December 07, 2023 Filed Dec 12, 2023 00:51 UTC	OmniAb, Inc. OABI · Entity 5294	Tax withholdingCommon Stock	16,081	$4.85	$77,992.85	Disclosure SEC source: 0002001011-23-000010 · primary_doc.xml · nonDerivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · Executive VP, Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,705 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units ("RSUs"). Read SEC document
December 07, 2023 Filed Dec 12, 2023 00:51 UTC	OmniAb, Inc. OABI · Entity 5294	Exercise / conversionCommon Stock	46,503	Not disclosed	Not disclosed	Disclosure SEC source: 0002001011-23-000010 · primary_doc.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · Executive VP, Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three substantially equal annual installments beginning on December 07, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. F2 · balance_after: The total includes 8,334 shares acquired on May 31, 2023, and 11,160 shares acquired on November 30, 2023, through the Issuer's Employee Stock Purchase Plan (ESPP). Read SEC document
June 20, 2023 Filed Jun 22, 2023 21:55 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	10,013	$0.00 Strike: $26.19	$0.00	Disclosure SEC source: 0001127602-23-019288 · form4.xml · derivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,013 Underlying: Common Stock · 10,013 shares Expires 2033-06-20 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 20, 2023, such that the total number of shares will be fully vested on June 20, 2024. Read SEC document
June 20, 2023 Filed Jun 22, 2023 21:55 UTC	Xencor Inc XNCR · Entity 4487	GrantCommon Stock	5,007	$0.00	$0.00	Disclosure SEC source: 0001127602-23-019288 · form4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,007 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document
April 07, 2023 Filed Apr 11, 2023 23:11 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option · Derivative	243,750	$0.00 Strike: $3.75	$0.00	Disclosure SEC source: 0001846253-23-000043 · edgardoc.xml · derivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · Executive VP, Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,750 Underlying: Common Stock · 243,750 shares Expires 2033-04-07 F2 · derivative.exercise_date: The Stock Option vests and is exercisable as to 12.5% of the underlying shares 6 months after the Grant Date, and in 42 substantially equal monthly installments thereafter. Read SEC document
April 07, 2023 Filed Apr 11, 2023 23:11 UTC	OmniAb, Inc. OABI · Entity 5294	GrantCommon Stock	40,625	$0.00	$0.00	Disclosure SEC source: 0001846253-23-000043 · edgardoc.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · Executive VP, Finance & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,416 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments beginning on each anniversary following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document
April 01, 2023 Filed Apr 4, 2023 20:57 UTC	OmniAb, Inc. OABI · Entity 5294	Tax withholdingCommon Stock	8,042	$3.68	$29,594.56	Disclosure SEC source: 0001846253-23-000035 · edgardoc.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP, Finance and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,791 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units. Read SEC document
January 03, 2023 Filed Jan 5, 2023 22:07 UTC	OmniAb, Inc. OABI · Entity 5294	GrantCommon Stock	139,504	$0.00	$0.00	Disclosure SEC source: 0000899243-23-001021 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,833 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments beginning on December 7, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document
December 07, 2022 Filed Dec 9, 2022 23:00 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option · Derivative	697,520	$0.00 Strike: $3.68	$0.00	Disclosure SEC source: 0000899243-22-038124 · doc4.xml · derivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 697,520 Underlying: Common Stock · 697,520 shares Expires 2032-12-07 F1 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on June 7, 2023, and in 42 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document
December 01, 2022 Filed Dec 6, 2022 02:37 UTC	OmniAb, Inc. OABI · Entity 5294	Tax withholdingCommon Stock	6,733	$3.35	$22,555.55	Disclosure SEC source: 0000899243-22-037742 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,329 Read SEC document
November 28, 2022 Filed Nov 29, 2022 23:18 UTC	OmniAb, Inc. OABI · Entity 5294	PurchaseCommon Stock	10,000	$2.81	$28,100.00	Disclosure SEC source: 0000899243-22-037153 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,062 Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:13 UTC	OmniAb Operations, Inc. NONE · Entity 122629	Disposition to issuerStock Option · Derivative	71,174	Not disclosed Strike: $60.68	Not disclosed	Disclosure SEC source: 0000899243-22-035057 · doc4.xml · derivative · entry 4 GUSTAFSON KURT A · CIK 0001462354 · EVP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,174 shares Expires 2032-04-08 F2 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F2 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on October 8, 2022, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:13 UTC	OmniAb Operations, Inc. NONE · Entity 122629	GrantStock Option · Derivative	71,174	$0.00 Strike: $60.68	$0.00	Disclosure SEC source: 0000899243-22-035057 · doc4.xml · derivative · entry 3 GUSTAFSON KURT A · CIK 0001462354 · EVP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,174 Underlying: Common Stock · 71,174 shares Expires 2032-04-08 F3 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on October 8, 2022, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:13 UTC	OmniAb Operations, Inc. NONE · Entity 122629	Disposition to issuerCommon Stock	17,792	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-035057 · doc4.xml · nonDerivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · EVP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F2 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:13 UTC	OmniAb Operations, Inc. NONE · Entity 122629	GrantCommon Stock	17,792	$0.00	$0.00	Disclosure SEC source: 0000899243-22-035057 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,792 F1 · shares: Includes 14,234 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:12 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option · Derivative	348,760	Not disclosed Strike: $12.39	Not disclosed	Disclosure SEC source: 0000899243-22-035053 · doc4.xml · derivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · EVP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,760 Underlying: Common Stock · 348,760 shares Expires 2032-04-08 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on October 8, 2022, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:12 UTC	OmniAb, Inc. OABI · Entity 5294	GrantCommon Stock	160,062	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-035053 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,062 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F2 · shares: Includes 69,752 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F3 · shares: Includes 72,872 earn-out shares subject to forfeiture provisions described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. Read SEC document
June 23, 2022 Filed Jun 27, 2022 20:52 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	21,412	$0.00 Strike: $26.58	$0.00	Disclosure SEC source: 0001127602-22-018172 · form4.xml · derivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,412 Underlying: Common Stock · 21,412 shares Expires 2032-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 23, 2022, such that the total number of shares will be fully vested on June 23, 2023. Read SEC document
March 16, 2022 Filed Mar 16, 2022 18:15 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	16,318	$0.71	$11,520.51	Disclosure SEC source: 0001209191-22-019297 · doc4.xml · nonDerivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,259 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
March 15, 2022 Filed Mar 16, 2022 18:15 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	20,653	$0.71	$14,560.37	Disclosure SEC source: 0001209191-22-019297 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,577 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
February 24, 2022 Filed Feb 24, 2022 18:43 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	15,958	$0.64	$10,213.12	Disclosure SEC source: 0001209191-22-012804 · doc4.xml · nonDerivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,230 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
February 23, 2022 Filed Feb 24, 2022 18:43 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	20,215	$0.70	$14,211.15	Disclosure SEC source: 0001209191-22-012804 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,188 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. F2 · balance_after: Since the date of the reporting person's last ownership report, he transferred 14,429 shares of the Company's common stock to his ex-wife pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
June 24, 2021 Filed Jun 26, 2021 00:01 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	9,728	$0.00 Strike: $36.01	$0.00	Disclosure SEC source: 0001415889-21-003233 · form4-06252021_080627.xml · derivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,728 Underlying: Common Stock · 9,728 shares Expires 2031-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 24, 2021, such that the total number of shares will be fully vested on June 24, 2022. Read SEC document
June 17, 2021 Filed Jun 22, 2021 21:21 UTC	Niagen Bioscience, Inc. CDXC · Entity 6146	GrantStock Options (right to buy) · Derivative	20,000	$0.00 Strike: $9.99	$0.00	Disclosure SEC source: 0001628280-21-012665 · wf-form4_162439684890561.xml · derivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: Options vest 100% on June 17, 2022 Read SEC document
March 16, 2021 Filed Mar 17, 2021 18:08 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	16,318	$3.69	$60,213.42	Disclosure SEC source: 0001209191-21-021495 · doc4.xml · nonDerivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,451 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
March 15, 2021 Filed Mar 17, 2021 18:08 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	20,365	$3.63	$73,823.13	Disclosure SEC source: 0001209191-21-021495 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,769 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
February 22, 2021 Filed Feb 23, 2021 16:27 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	4,000	$3.73	$14,920.00	Disclosure SEC source: 0001209191-21-013219 · doc4.xml · nonDerivative · entry 3 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,134 F2 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
February 19, 2021 Filed Feb 23, 2021 16:27 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	4,672	$3.64	$16,992.06	Disclosure SEC source: 0001209191-21-013219 · doc4.xml · nonDerivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,134 F2 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
February 18, 2021 Filed Feb 23, 2021 16:27 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantStock Appreciation Right · Derivative	340,618	$0.00 Strike: $3.56	$0.00	Disclosure SEC source: 0001209191-21-013219 · doc4.xml · derivative · entry 6 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,618 Underlying: Common Stock · 340,618 shares Expires 2031-02-18 F4 · derivative.exercise_date: One third of the aggregate amount of stock appreciation rights shall vest on each of February 18, 2022, 2023 and 2024, respectively. Read SEC document
February 18, 2021 Filed Feb 23, 2021 16:27 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantStock Option (Right to Buy) · Derivative	144,944	$0.00 Strike: $3.56	$0.00	Disclosure SEC source: 0001209191-21-013219 · doc4.xml · derivative · entry 5 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,944 Underlying: Common Stock · 144,944 shares Expires 2031-02-18 F3 · derivative.exercise_date: One third of the aggregate amount of option shares shall vest on each of February 18, 2022, 2023 and 2024, respectively. Read SEC document
February 18, 2021 Filed Feb 23, 2021 16:27 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantCommon Stock, $0.001 par value	119,579	$0.00	$0.00	Disclosure SEC source: 0001209191-21-013219 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,806 F1 · shares: One third of the aggregate amount of restricted shares shall vest on each of February 18, 2022, 2023 and 2024, respectively. Read SEC document
January 20, 2021 Filed Jan 20, 2021 20:33 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001	1,944	$4.31	$8,378.64	Disclosure SEC source: 0001209191-21-004579 · doc4.xml · nonDerivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,608 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
January 19, 2021 Filed Jan 20, 2021 20:33 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001	2,582	$3.81	$9,832.26	Disclosure SEC source: 0001209191-21-004579 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,552 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
December 14, 2020 Filed Dec 16, 2020 17:16 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001	25,696	$5.00	$128,480.00	Disclosure SEC source: 0001209191-20-063841 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,134 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
June 25, 2020 Filed Jun 30, 2020 00:41 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	13,953	$0.00 Strike: $33.42	$0.00	Disclosure SEC source: 0001209191-20-039312 · doc4.xml · derivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,953 Underlying: Common Stock · 13,953 shares Expires 2030-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 25, 2020, such that the total number of shares will be fully vested on June 25, 2021. Read SEC document
June 19, 2020 Filed Jun 23, 2020 01:14 UTC	Niagen Bioscience, Inc. CDXC · Entity 6146	GrantStock Options (right to buy) · Derivative	20,000	$0.00 Strike: $4.67	$0.00	Disclosure SEC source: 0001415889-20-001659 · form4-06222020_060657.xml · derivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: Options vest 100% on June 19, 2021. Read SEC document
April 01, 2020 Filed Apr 2, 2020 18:16 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001	3,135	$2.23	$6,991.05	Disclosure SEC source: 0001209191-20-022779 · doc4.xml · nonDerivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,830 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
March 31, 2020 Filed Apr 2, 2020 18:16 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001	4,326	$2.31	$9,988.73	Disclosure SEC source: 0001209191-20-022779 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,965 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
March 12, 2020 Filed Mar 13, 2020 17:28 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantStock Appreciation Right · Derivative	225,000	$0.00 Strike: $2.13	$0.00	Disclosure SEC source: 0001209191-20-018989 · doc4.xml · derivative · entry 4 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2030-03-12 F3 · derivative.exercise_date: 25% of the stock appreciation rights vested on March 12, 2020. The remaining stock appreciation rights shall vest in equal amounts of 25% of the total shares underlying the stock appreciation rights on each anniversary of the grant date over the next three years. The stock appreciation rights can be settled in common stock or cash at the election of the Compensation Committee. Read SEC document
March 12, 2020 Filed Mar 13, 2020 17:28 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantStock Option (Right to Buy) · Derivative	260,000	$0.00 Strike: $2.13	$0.00	Disclosure SEC source: 0001209191-20-018989 · doc4.xml · derivative · entry 3 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2030-03-12 F2 · derivative.exercise_date: 25% of the option shares vested on March 12, 2020. The remaining option shares shall vest in equal amounts of 25% of the total shares underlying the option shares on each anniversary of the grant date over the next three years. Read SEC document
March 12, 2020 Filed Mar 13, 2020 17:28 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantCommon Stock, $0.001	163,180	$0.00	$0.00	Disclosure SEC source: 0001209191-20-018989 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,291 F1 · shares: One third of the aggregate amount of restricted shares shall vest on each of March 12, 2021, 2022 and 2023, respectively. Read SEC document
February 20, 2020 Filed Feb 21, 2020 19:09 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001	3,333	$2.85	$9,499.05	Disclosure SEC source: 0001209191-20-011772 · doc4.xml · nonDerivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,111 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
February 19, 2020 Filed Feb 21, 2020 19:09 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001	4,733	$2.77	$13,115.14	Disclosure SEC source: 0001209191-20-011772 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,444 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. F2 · balance_after: Since the date of the reporting person's last ownership report, he transferred 18,778 shares of the Company's common stock to his ex-wife pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-wife. Read SEC document
January 17, 2020 Filed Jan 17, 2020 18:24 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001	1,621	$3.33	$5,397.93	Disclosure SEC source: 0001209191-20-004154 · doc4.xml · nonDerivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,955 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
January 16, 2020 Filed Jan 17, 2020 18:24 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001	2,522	$3.37	$8,491.57	Disclosure SEC source: 0001209191-20-004154 · doc4.xml · nonDerivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,576 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
June 26, 2019 Filed Jun 27, 2019 23:46 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	12,731	$0.00 Strike: $39.08	$0.00	Disclosure SEC source: 0001209191-19-039383 · doc4.xml · derivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,731 Underlying: Common Stock · 12,731 shares Expires 2029-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 26, 2019, such that the total number of shares will be fully vested on June 26, 2020. Read SEC document
June 21, 2019 Filed Jun 25, 2019 00:30 UTC	Niagen Bioscience, Inc. CDXC · Entity 6146	GrantStock Options (right to buy) · Derivative	20,000	$0.00 Strike: $3.80	$0.00	Disclosure SEC source: 0001415889-19-000790 · form4-06242019_050613.xml · derivative · entry 1 GUSTAFSON KURT A · CIK 0001462354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-21 F1 · derivative.exercise_date: Options vest 100% on June 21, 2020. Read SEC document
April 01, 2019 Filed Apr 1, 2019 18:14 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001	3,000	$10.73	$32,190.00	Disclosure SEC source: 0001209191-19-022062 · doc4.xml · nonDerivative · entry 3 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,098 F2 · kind: The shares were sold in this transaction by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document
April 01, 2019 Filed Apr 1, 2019 18:14 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001	1,642	$10.81	$17,750.02	Disclosure SEC source: 0001209191-19-022062 · doc4.xml · nonDerivative · entry 2 GUSTAFSON KURT A · CIK 0001462354 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,098 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.